Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 11 trials

Success Rate

100.0%

+13.4% vs industry average

Late-Stage Pipeline

1 trials in Phase 3/4

Results Transparency

0 of 1 completed trials have results

Key Signals

6 recruiting

Enrollment Performance

Analytics

N/A

2(50.0%)

Phase 4

1(25.0%)

Phase 2

1(25.0%)

4Total

N/A(2)

Phase 4(1)

Phase 2(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (11)

Showing 11 of 11 trials

NCT07688447Not ApplicableRecruiting

Multicenter Randomized Controlled Trial of ThuLEP Versus ThuLEP Combined With Bladder Neck Incision in Patients With Small-Volume Benign Prostatic Hyperplasia

Role: lead

NCT07733050Phase 2Not Yet Recruiting

Efficacy and Safety of Serplulimab in Combination With Bevacizumab and FOLFIRINOX or NALIRIFOX as Second-Line Therapy in Patients With Metastatic Pancreatic Ductal Adenocarcinoma

Role: lead

NCT07281170Recruiting

Xinqiao High-risk Cohort of Diabetes(NICE)

Role: lead

NCT06566898Recruiting

Monitoring of Antimicrobial Resistance Based on Metagenomics Analyses in Pneumonia Patients

Role: lead

NCT07257952Not Yet Recruiting

APOs Associated With Respiratory Viral Infections Before and During Early Pregnancy

Role: lead

NCT06740552Completed

Evolocumab in Patients With Multivessel Coronary Disease After Acute Myocardial Infarction: A Target Trial Emulation